Intellia Therapeutics (NTLA) Interest Expenses (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Interest Expenses data on file, last reported at $96.8 million in Q1 2026.

• On a quarterly basis, Interest Expenses fell 32.15% year-over-year to $96.8 million in Q1 2026; TTM through Mar 2026 was $96.8 million, a 32.15% decrease from a year earlier, with the FY2025 full-year figure at $914.6 million, up 16.78% from the prior year.
• Interest Expenses for Q1 2026 stood at $96.8 million, up from $50000.0 in the prior quarter.
• Over the last five years, Interest Expenses for NTLA reached as high as $204.9 million in Q1 2022 and fell as low as $50000.0 in Q4 2025.
• Historically, Interest Expenses has averaged $62.6 million across 5 years, with a median of $39.8 million in 2023.
• Across the five-year window, Interest Expenses plunged 98.11% in 2024 and surged 945.79% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $3.8 million in 2022, then jumped by 839.63% to $35.9 million in 2023, then plunged by 98.11% to $678000.0 in 2024, then plunged by 92.63% to $50000.0 in 2025, then jumped by 193578.0% to $96.8 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $96.8 million in Q1 2026, $50000.0 in Q4 2025, and $117.7 million in Q3 2025.